Phosphodiesterase Inhibitors in the Treatment of Inflammatory Diseases
- Author
- PAGE, C. P1 ; SPINA, D1
[1] Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, School of Biomedical Sciences, King's College London, Franklin Wilkins Building, London SE1 9NH, United Kingdom - Issue title
- Phosphodiesterases as Drug Targets
- Author (monograph)
- HOUSLAY, Miles D (Author of introductory parts)3 ; CONTI, Marco (Author of introductory parts)1 ; FRANCIS, Sharron H (Author of introductory parts)2
[1] Center for Reproductive Sciences, University of California, San Fransisco, CA 94143-0556, United States
[2] Department of Molecular Physiology and Niophysics, Vanderbilt University School of Medicine, Nashville, TN 37232-0615, United States
[3] Molecular Pharmacology Group, Institute of Neuroscience and Psychology, CMVLS, University of GLasgow, Glasgow G11 8QQ, Scoltand, United Kingdom - Source
Handbook of experimental pharmacology. 2011, Vol 204, pp 391-414, 24 p ; ref : 6 p.3/4
- ISSN
- 0171-2004
- Scientific domain
- Pharmacology drugs
- Publisher
- Springer, Heidelberg
- Publication country
- Germany
- Document type
- Article
- Language
- English
- Author keyword
- Asthma COPD Cilomilast Emesis Inflammation PDE4 Roflumilast
- Keyword (fr)
- Article synthèse Asthme Bronchopneumopathie chronique obstructive Bronchopneumopathie obstructive Cilomilast Inflammation Inhibiteur de la phosphodiestérase 4 Maladie inflammatoire Mécanisme action Physiopathologie Roflumilast Traitement Vomissement 3',5'-Cyclic-nucleotide phosphodiesterase Enzyme Esterases Hydrolases Inhibiteur enzyme Pathologie de l'appareil digestif Pathologie de l'appareil respiratoire Pathologie des bronches Pathologie des poumons Phosphoric diester hydrolases
- Keyword (en)
- Review Asthma Chronic obstructive pulmonary disease Obstructive pulmonary disease Cilomilast Inflammation Phosphodiesterase 4 inhibitor Inflammatory disease Mechanism of action Pathophysiology Roflumilast Treatment Vomiting 3',5'-Cyclic-nucleotide phosphodiesterase Enzyme Esterases Hydrolases Enzyme inhibitor Digestive diseases Respiratory disease Bronchus disease Lung disease Phosphoric diester hydrolases
- Keyword (es)
- Artículo síntesis Asma Enfermedad pulmonar obstructiva crónica Enfermedad pulmonar obstructiva Cilomilast Inflamación Inhibidor fosfodiesterasa 4 Enfermedad inflamatoria Mecanismo acción Fisiopatología Roflumilast Tratamiento Vómito 3',5'-Cyclic-nucleotide phosphodiesterase Enzima Esterases Hydrolases Inhibidor enzima Aparato digestivo patología Aparato respiratorio patología Bronquio patología Pulmón patología Phosphoric diester hydrolases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02D Respiratory system
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B11 Pneumology / 002B11B Chronic obstructive pulmonary disease, asthma
- Discipline
- Pharmacological treatments Pulmonology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 24484792
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1007/978-3-642-17969-3_17 
https://dx.doi.org/10.1007/978-3-642-17969-3_17
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1007\/978-3-642-17969-3_17\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:70:\"Phosphodiesterase Inhibitors in the Treatment of Inflammatory Diseases\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Handbook of experimental pharmacology\";s:9:\"\u0000*\u0000stitle\";s:21:\"Handb. exp. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:3:\"204\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"391\";s:8:\"\u0000*\u0000epage\";s:3:\"414\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0171-2004\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"PAGE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"C. P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:1:{i:0;s:8:\"SPINA, D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:34:\"Phosphodiesterases as Drug Targets\";s:8:\"\u0000*\u0000title\";s:70:\"Phosphodiesterase Inhibitors in the Treatment of Inflammatory Diseases\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"24\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1007\/978-3-642-17969-3_17\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:70:\"Phosphodiesterase Inhibitors in the Treatment of Inflammatory Diseases\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Handbook of experimental pharmacology\";s:9:\"\u0000*\u0000stitle\";s:21:\"Handb. exp. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:3:\"204\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"391\";s:8:\"\u0000*\u0000epage\";s:3:\"414\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0171-2004\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"PAGE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"C. P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:1:{i:0;s:8:\"SPINA, D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:34:\"Phosphodiesterases as Drug Targets\";s:8:\"\u0000*\u0000title\";s:70:\"Phosphodiesterase Inhibitors in the Treatment of Inflammatory Diseases\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"24\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:28:\"10.1007\/978-3-642-17969-3_17\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1007\/978-3-642-17969-3_17\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:70:\"Phosphodiesterase Inhibitors in the Treatment of Inflammatory Diseases\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Handbook of experimental pharmacology\";s:9:\"\u0000*\u0000stitle\";s:21:\"Handb. exp. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:3:\"204\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"391\";s:8:\"\u0000*\u0000epage\";s:3:\"414\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0171-2004\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"PAGE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"C. P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:1:{i:0;s:8:\"SPINA, D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:34:\"Phosphodiesterases as Drug Targets\";s:8:\"\u0000*\u0000title\";s:70:\"Phosphodiesterase Inhibitors in the Treatment of Inflammatory Diseases\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"24\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1007\/978-3-642-17969-3_17\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:70:\"Phosphodiesterase Inhibitors in the Treatment of Inflammatory Diseases\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Handbook of experimental pharmacology\";s:9:\"\u0000*\u0000stitle\";s:21:\"Handb. exp. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:3:\"204\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"391\";s:8:\"\u0000*\u0000epage\";s:3:\"414\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0171-2004\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"PAGE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"C. P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:1:{i:0;s:8:\"SPINA, D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:34:\"Phosphodiesterases as Drug Targets\";s:8:\"\u0000*\u0000title\";s:70:\"Phosphodiesterase Inhibitors in the Treatment of Inflammatory Diseases\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"24\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1007\/978-3-642-17969-3_17\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:70:\"Phosphodiesterase Inhibitors in the Treatment of Inflammatory Diseases\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Handbook of experimental pharmacology\";s:9:\"\u0000*\u0000stitle\";s:21:\"Handb. exp. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:3:\"204\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"391\";s:8:\"\u0000*\u0000epage\";s:3:\"414\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0171-2004\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"PAGE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"C. P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:1:{i:0;s:8:\"SPINA, D\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:34:\"Phosphodiesterases as Drug Targets\";s:8:\"\u0000*\u0000title\";s:70:\"Phosphodiesterase Inhibitors in the Treatment of Inflammatory Diseases\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"24\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
